CCEL Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of 3.55% compared to Cryo-Cell International's net margin of -1.05%. Cryo-Cell International's return on equity of -- beat Astrana Health's return on equity of 9.13%.

Cryo-Cell International has a consensus price target of $8.50, signalling upside risk potential of 74.21%. On the other hand Astrana Health has an analysts' consensus of $50.5000 which suggests that it could grow by 55.91%. Given that Cryo-Cell International has higher upside potential than Astrana Health, analysts believe Cryo-Cell International is more attractive than Astrana Health.

Cryo-Cell International has a beta of 0.724, which suggesting that the stock is 27.595% less volatile than S&P 500. In comparison Astrana Health has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.209%.

Cryo-Cell International has a quarterly dividend of $0.25 per share corresponding to a yield of 10.25%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays 502.5% of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Cryo-Cell International's is not.

Cryo-Cell International quarterly revenues are $8M, which are smaller than Astrana Health quarterly revenues of $665.2M. Cryo-Cell International's net income of $282.9K is higher than Astrana Health's net income of -$7M. Notably, Cryo-Cell International's price-to-earnings ratio is 487.92x while Astrana Health's PE ratio is 36.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 1.24x versus 0.76x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of 3.55% compared to Cryo-Cell International's net margin of 7.43%. Cryo-Cell International's return on equity of -- beat Biote's return on equity of --.

Cryo-Cell International has a consensus price target of $8.50, signalling upside risk potential of 74.21%. On the other hand Biote has an analysts' consensus of $7.47 which suggests that it could grow by 129.74%. Given that Biote has higher upside potential than Cryo-Cell International, analysts believe Biote is more attractive than Cryo-Cell International.

Cryo-Cell International has a beta of 0.724, which suggesting that the stock is 27.595% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cryo-Cell International has a quarterly dividend of $0.25 per share corresponding to a yield of 10.25%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays 502.5% of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cryo-Cell International quarterly revenues are $8M, which are smaller than Biote quarterly revenues of $49.8M. Cryo-Cell International's net income of $282.9K is lower than Biote's net income of $3.7M. Notably, Cryo-Cell International's price-to-earnings ratio is 487.92x while Biote's PE ratio is 18.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 1.24x versus 0.57x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of 3.55% compared to Cryo-Cell International's net margin of 5.16%. Cryo-Cell International's return on equity of -- beat Omnicell's return on equity of 1.04%.

Cryo-Cell International has a consensus price target of $8.50, signalling upside risk potential of 74.21%. On the other hand Omnicell has an analysts' consensus of $50.71 which suggests that it could grow by 66.33%. Given that Cryo-Cell International has higher upside potential than Omnicell, analysts believe Cryo-Cell International is more attractive than Omnicell.

Cryo-Cell International has a beta of 0.724, which suggesting that the stock is 27.595% less volatile than S&P 500. In comparison Omnicell has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.397%.

Cryo-Cell International has a quarterly dividend of $0.25 per share corresponding to a yield of 10.25%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays 502.5% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

Cryo-Cell International quarterly revenues are $8M, which are smaller than Omnicell quarterly revenues of $306.9M. Cryo-Cell International's net income of $282.9K is lower than Omnicell's net income of $15.8M. Notably, Cryo-Cell International's price-to-earnings ratio is 487.92x while Omnicell's PE ratio is 112.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 1.24x versus 1.27x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 3.55% compared to Cryo-Cell International's net margin of -12.84%. Cryo-Cell International's return on equity of -- beat P3 Health Partners's return on equity of -26.35%.

Cryo-Cell International has a consensus price target of $8.50, signalling upside risk potential of 74.21%. On the other hand P3 Health Partners has an analysts' consensus of $16.25 which suggests that it could grow by 84.87%. Given that P3 Health Partners has higher upside potential than Cryo-Cell International, analysts believe P3 Health Partners is more attractive than Cryo-Cell International.

Cryo-Cell International has a beta of 0.724, which suggesting that the stock is 27.595% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cryo-Cell International has a quarterly dividend of $0.25 per share corresponding to a yield of 10.25%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cryo-Cell International pays 502.5% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Cryo-Cell International quarterly revenues are $8M, which are smaller than P3 Health Partners quarterly revenues of $362.1M. Cryo-Cell International's net income of $282.9K is higher than P3 Health Partners's net income of -$46.5M. Notably, Cryo-Cell International's price-to-earnings ratio is 487.92x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cryo-Cell International is 1.24x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.